共 41 条
[1]
Brugger W(2011)Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer J Clin Oncol 29 4113-4120
[2]
Triller N(2010)SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 521-529
[3]
Blasinska-Morawiec M(2016)Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study) Lung Cancer 102 30-37
[4]
Cappuzzo F(2012)SATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy Ann Oncol 23 388-394
[5]
Ciuleanu T(2015)Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON study Cancer Epidemiol 39 291-297
[6]
Stelmakh L(2010)Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line Oncology 78 249-258
[7]
Cicènas S(2009)Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers J Clin Oncol 27 1220-1226
[8]
Geater SL(2012)Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation Drugs 72 3-10
[9]
Petrov P(2016)ESMO guidelines committee. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 27 v1-v27
[10]
Coudert B(2012)Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients Drugs 72 11-19